Pharma BD Deal Intelligence

Treeline Biosciences, Inc. / Standard BioTools Inc.

2026 · Reverse Merger · Pending

Standard BioTools Inc. and Treeline Biosciences announced an all-stock merger agreement on 2026-06-08. Pre-merger Treeline stockholders are expected to own approximately 84% of the combined company and Standard BioTools stockholders approximately 16%. Standard BioTools contributes roughly $450 million in net cash, with the combined company expected to hold more than $900 million in pro-forma cash at closing, funding operations into 2029. The combined company is expected to operate as Treeline Biosciences and trade on Nasdaq under 'TRLN'. No headline transaction value was disclosed. The FTC granted early termination of the HSR waiting period on 2026-07-21 and a Form S-4 was filed on 2026-07-20; closing is expected by end of 2026 subject to Standard BioTools stockholder approval.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2026 deals